Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2017 at the end of the 10-year period of market exclusivity.
On 30 May 2001, orphan designation (EU/3/01/039) was granted by the European Commission to Pharma Mar SA, Spain, for ecteinascidin 743 for the treatment of soft tissue sarcoma.
Ecteinascidin 743 in treatment of soft tissue sarcoma has been authorised in the EU as Yondelis since 17 September 2007.
This medicine is now known as trabectedin.
Ecteinascidin 743 (trabectedin)
|Disease / condition||
Treatment of soft tissue sarcoma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.